Relationships Among Microbiota, Gastric Cancer, and Immunotherapy

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2022 Sep 29

PMID 36171746

Authors

Yuzhen Li

Xiaona Huang

Desheng Tong

Chenyu Jiang

Xiaodan Zhu

Zhipeng Wei

Tingjie Gong

Chunhui Jin

Affiliations

Soon will be listed here.

Abstract

Currently, conventional neoadjuvant therapy or postoperative adjuvant therapy, such as chemotherapy and radiation therapy, can only bring limited survival benefits to gastric cancer (GC). Median survival after palliative chemotherapy is also low, at about 8-10 months. Immunotargeting is a new option for the treatment of GC, but has not been widely replicated. The highly immunosuppressed tumor microenvironment (TME) discounts the efficacy of immunotherapy for GC. Therefore, new strategies are needed to enhance the immune response of the TME. This paper reviewed the relationship between microorganisms and GC, potential links between microorganisms and immunotherapy and research of microorganisms combined immunotherapy.

Citing Articles

Unveiling the gastric microbiota: implications for gastric carcinogenesis, immune responses, and clinical prospects.

Liu Z, Zhang D, Chen S J Exp Clin Cancer Res. 2024; 43(1):118.

PMID: 38641815 PMC: 11027554. DOI: 10.1186/s13046-024-03034-7.

Microbiota-Gastric Cancer Interactions and the Potential Influence of Nutritional Therapies.

Raoul P, Maccauro V, Cintoni M, Scarpellini E, Ianiro G, Gasbarrini A Int J Mol Sci. 2024; 25(3).

PMID: 38338956 PMC: 10855965. DOI: 10.3390/ijms25031679.

Gut microbiome-derived butyrate inhibits the immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages in gastric cancer.

Lee S, Jhun J, Woo J, Lee K, Hwang S, Moon J Gut Microbes. 2024; 16(1):2300846.

PMID: 38197259 PMC: 10793689. DOI: 10.1080/19490976.2023.2300846.

Exploring the Microbiome in Gastric Cancer: Assessing Potential Implications and Contextualizing Microorganisms beyond and Epstein-Barr Virus.

Shin W, Xie F, Chen B, Yu J, Lo K, Tse G Cancers (Basel). 2023; 15(20).

PMID: 37894360 PMC: 10605912. DOI: 10.3390/cancers15204993.

Effect of microbiome group on immune checkpoint inhibitors in treatment of gastrointestinal tumors.

Pei B, Ma X, Wu N, Wang C, Yang W Chin J Cancer Res. 2023; 35(3):252-265.

PMID: 37440825 PMC: 10334499. DOI: 10.21147/j.issn.1000-9604.2023.03.05.

References

Michaud D . Role of bacterial infections in pancreatic cancer. Carcinogenesis. 2013; 34(10):2193-7. PMC: 3786384. DOI: 10.1093/carcin/bgt249. View

Tsang Y, Lamb A, Romero-Gallo J, Huang B, Ito K, Peek Jr R . Helicobacter pylori CagA targets gastric tumor suppressor RUNX3 for proteasome-mediated degradation. Oncogene. 2010; 29(41):5643-50. PMC: 2980823. DOI: 10.1038/onc.2010.304. View

Pianta A, Arvikar S, Strle K, Drouin E, Wang Q, Costello C . Evidence of the Immune Relevance of Prevotella copri, a Gut Microbe, in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2016; 69(5):964-975. PMC: 5406252. DOI: 10.1002/art.40003. View

Inamura K . Gut microbiota contributes towards immunomodulation against cancer: New frontiers in precision cancer therapeutics. Semin Cancer Biol. 2020; 70:11-23. DOI: 10.1016/j.semcancer.2020.06.006. View

Singh V, Yang J, Chen T, Zachos N, Kovbasnjuk O, Verkman A . Translating molecular physiology of intestinal transport into pharmacologic treatment of diarrhea: stimulation of Na+ absorption. Clin Gastroenterol Hepatol. 2013; 12(1):27-31. PMC: 3926754. DOI: 10.1016/j.cgh.2013.10.020. View

Tomita H, Takaishi S, Menheniott T, Yang X, Shibata W, Jin G . Inhibition of gastric carcinogenesis by the hormone gastrin is mediated by suppression of TFF1 epigenetic silencing. Gastroenterology. 2010; 140(3):879-91. PMC: 3049860. DOI: 10.1053/j.gastro.2010.11.037. View

Yan F, Cao H, Chaturvedi R, Krishna U, Hobbs S, Dempsey P . Epidermal growth factor receptor activation protects gastric epithelial cells from Helicobacter pylori-induced apoptosis. Gastroenterology. 2009; 136(4):1297-1307, e1-3. PMC: 2878739. DOI: 10.1053/j.gastro.2008.12.059. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

Zhang Z, Zhu L, Ma Y, Wang B, Ci C, Zhang J . Study on the Characteristics of Intestinal Flora Composition in Gastric Cancer Patients and Healthy People in the Qinghai-Tibet Plateau. Appl Biochem Biotechnol. 2021; 194(4):1510-1526. PMC: 9007807. DOI: 10.1007/s12010-021-03732-4. View

10.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

11.

Chandra V, McAllister F . Therapeutic potential of microbial modulation in pancreatic cancer. Gut. 2021; . PMC: 8292583. DOI: 10.1136/gutjnl-2019-319807. View

12.

Lefebvre O, Chenard M, Masson R, Linares J, Dierich A, Lemeur M . Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science. 1996; 274(5285):259-62. DOI: 10.1126/science.274.5285.259. View

13.

Brandi G, De Lorenzo S, Candela M, Pantaleo M, Bellentani S, Tovoli F . Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis. 2017; 38(3):231-240. DOI: 10.1093/carcin/bgx007. View

14.

Erawijantari P, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T . Influence of gastrectomy for gastric cancer treatment on faecal microbiome and metabolome profiles. Gut. 2020; 69(8):1404-1415. PMC: 7398469. DOI: 10.1136/gutjnl-2019-319188. View

15.

Qiu Q, Lin Y, Ma Y, Li X, Liang J, Chen Z . Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy. Front Immunol. 2021; 11:612202. PMC: 7817884. DOI: 10.3389/fimmu.2020.612202. View

16.

Peng C, Ouyang Y, Lu N, Li N . The NF-κB Signaling Pathway, the Microbiota, and Gastrointestinal Tumorigenesis: Recent Advances. Front Immunol. 2020; 11:1387. PMC: 7338561. DOI: 10.3389/fimmu.2020.01387. View

17.

Greally M, Chou J, Chatila W, Margolis M, Capanu M, Hechtman J . Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Clin Cancer Res. 2019; 25(20):6160-6169. PMC: 6905384. DOI: 10.1158/1078-0432.CCR-18-3603. View

18.

Chen D, Wu J, Jin D, Wang B, Cao H . Fecal microbiota transplantation in cancer management: Current status and perspectives. Int J Cancer. 2018; 145(8):2021-2031. PMC: 6767494. DOI: 10.1002/ijc.32003. View

19.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

20.

Oh S, Sohn B, Cheong J, Kim S, Lee J, Park K . Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018; 9(1):1777. PMC: 5934392. DOI: 10.1038/s41467-018-04179-8. View